MagenHMuchtarE.Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195. doi:10.1177/2040620716652862
2.
DimopoulosMAOriolANahiH, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1590-1599. doi:10.1200/JCO.22.00940
3.
MoreauPDimopoulosMAMikhaelJ, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4
4.
BansalDFavasMKYoosufBT.Bayesian methods of signal detection. In: KumarA, ed. Signal Analysis in Pharmacovigilance. Boca Raton, FL: CRC Press; 2024:135-147. doi:10.1201/9781032629940
5.
ZhangYShanCZhangXLiuYXiaYWangY.Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study. Front Immunol. 2024;15:1400101. doi:10.3389/fimmu.2024.1400101
6.
JiangTSuHLiY, et al. Post-marketing safety of immunomodulatory drugs in multiple myeloma: a pharmacovigilance investigation based on the FDA adverse event reporting system. Front Pharmacol. 2022;13:989032. doi:10.3389/fphar.2022.989032
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
